Microcap Ledger Passage BIO, Inc. $PASG
Facts as of . Built from SEC filings and our own data. Small caps move fast; check the latest filings.
Snapshot
- Exchange
- Nasdaq Capital Market
- Sector
- Biological Products, (No Diagnostic Substances)
- Headquarters
- Philadelphia, PA
- Fiscal year end
- December 31
- Shares outstanding
- 3,217,810 [10-Q 2026-08-10]
What the company doesAI summary of filing
Passage BIO, Inc. is a clinical-stage genetic medicines company developing one-time gene therapies for neurodegenerative diseases. The company's lead program, PBFT02, is an AAV1-based gene replacement therapy in Phase 1/2 clinical trials (upliFT-D) for frontotemporal dementia caused by progranulin deficiency (FTD-GRN), with expansion cohorts planned for FTD-C9orf72 and potential future development in amyotrophic lateral sclerosis and Alzheimer's disease. The company also has a preclinical research program through collaboration with Gemma Biotherapeutics to develop a genetic medicine for Huntington's disease. Passage BIO does not currently generate revenue and is pre-revenue, funding operations through research and clinical development activities. [10-K 2026-03-03]
Financial health
| Period | Revenue | Net income | Operating cash flow | Cash | Filing |
|---|---|---|---|---|---|
| 6 months to Jun 2026 | — | −$15.38M | −$22.17M | $24.16M | [S-4/A 2026-09-03] |
| FY ended Dec 2025 | — | −$45.52M | −$31.51M | $46.30M | [S-4/A 2026-09-03] |
| FY ended Dec 2024 | — | −$64.77M | −$47.96M | $37.57M | [S-4/A 2026-09-03] |
- Quarterly cash burn
- −$11.08M
- Cash runway Estimate
- ~6.5 months
Capital structure and dilution
| Date | Shares outstanding | Filing |
|---|---|---|
| 2024-11-08 | 61,767,286 | [10-Q 2024-11-13] |
| 2025-02-27 | 62,148,274 | [10-K 2025-03-04] |
| 2025-05-08 | 62,148,274 | [10-Q 2025-05-13] |
| 2025-08-07 | 3,178,710 | [10-Q 2025-08-12] |
| 2025-11-06 | 3,178,710 | [10-Q 2025-11-10] |
| 2026-02-26 | 3,207,810 | [10-K 2026-03-03] |
| 2026-05-07 | 3,207,810 | [10-Q 2026-05-12] |
| 2026-08-05 | 3,217,810 | [10-Q 2026-08-10] |
- Shelf registration
- S-3 filed 2024-03-04; declared effective 2024-04-16 [S-3 2024-03-04]
Listing status
Current status: 1 Form 8-K Item 3.01 filing(s) in the last 24 months, most recent 2025-01-31. Item 3.01 covers delisting notices, failures to meet a listing rule and listing transfers; read the filing for which one.
| Date | Event | Details | Deadline | Filing |
|---|---|---|---|---|
| 2025-01-31 | 8-K Item 3.01 | Notice of delisting or failure to satisfy a continued listing rule or standard; or transfer of listing | — | [8-K 2025-01-31] |
Who owns it
| Date | Insider | Type | Shares | Price | Filing |
|---|---|---|---|---|---|
| 2026-06-25 | Lynx1 Capital Management Lp | buy | 50,055 | $4.12 | [4 2026-06-29] |
Catalysts and calendar
| Date | Type | Title |
|---|---|---|
| 2026-10-09 | 424B3 | Prospectus or prospectus supplement |
| 2026-09-03 | 8-K | Material agreement entered; Unregistered sale of equity |
| 2026-08-14 | 13G/A | Beneficial ownership report (5%+ holder) |
| 2026-08-10 | 10-Q | Quarterly report |
| 2026-07-02 | 13D | Beneficial ownership report (5%+ holder) |
| 2026-06-25 | 13G | Beneficial ownership report (5%+ holder) |
| 2026-06-24 | 8-K | Material agreement entered; Material agreement terminated; Unregistered sale of equity |
| 2026-05-27 | 8-K | Material agreement terminated |
| 2026-05-26 | 8-K | Shareholder vote results |
| 2026-05-12 | 10-Q | Quarterly report |
| 2026-04-28 | 8-K | Exit or disposal costs |
| 2026-04-20 | 8-K | Regulation FD disclosure |
Alerts for $PASG
Email me when Passage BIO, Inc. files an offering, gets a deficiency notice, or moves sharply.
Facts as of . Small caps move fast; check the latest filings.